Stable, soluble T-cell receptor molecules for crystallization and therapeutics.
about
T cell receptor gene therapy for cancerCrystallization and preliminary X-ray structural studies of a Melan-A pMHC-TCR complexA T cell receptor flattens a bulged antigenic peptide presented by a major histocompatibility complex class I moleculeStructural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptorCrystal Structures of Mouse CD1d-iGb3 Complex and its Cognate Vα14 T Cell Receptor Suggest a Model for Dual Recognition of Foreign and Self GlycolipidsGerm Line-governed Recognition of a Cancer Epitope by an Immunodominant Human T-cell ReceptorT Cell Receptor Cross-reactivity Directed by Antigen-Dependent Tuning of Peptide-MHC Molecular FlexibilityGenetic and Structural Basis for Selection of a Ubiquitous T Cell Receptor Deployed in Epstein-Barr Virus InfectionA highly tilted binding mode by a self-reactive T cell receptor results in altered engagement of peptide and MHCExtending the usability of the phasing power of diselenide bonds: SeCys SAD phasing of CsgC using a non-auxotrophic strainConformational Melding Permits a Conserved Binding Geometry in TCR Recognition of Foreign and Self Molecular MimicsMinimal conformational plasticity enables TCR cross-reactivity to different MHC class II heterodimersLoss of T Cell Antigen Recognition Arising from Changes in Peptide and Major Histocompatibility Complex Protein Flexibility: IMPLICATIONS FOR VACCINE DESIGNStructural features underlying T-cell receptor sensitivity to concealed MHC class I micropolymorphismsDisparate Degrees of Hypervariable Loop Flexibility Control T-Cell Receptor Cross-Reactivity, Specificity, and Binding MechanismT Cell Receptor Signaling Is Limited by Docking Geometry to Peptide-Major Histocompatibility ComplexStructural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restrictionStructural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes.Lysophospholipid presentation by CD1d and recognition by a human Natural Killer T-cell receptorT-cell Receptor Specificity Maintained by Altered ThermodynamicsIncreased peptide contacts govern high affinity binding of a modified TCR whilst maintaining a native pMHC docking modeStructure of TCR and antigen complexes at an immunodominant CTL epitope in HIV-1 infectionT-cell Receptor (TCR)-Peptide Specificity Overrides Affinity-enhancing TCR-Major Histocompatibility Complex InteractionsMolecular Basis of a Dominant T Cell Response to an HIV Reverse Transcriptase 8-mer Epitope Presented by the Protective Allele HLA-B*51:01Proline substitution independently enhances H-2D(b) complex stabilization and TCR recognition of melanoma-associated peptidesRecent advances in T-cell engineering for use in immunotherapyStructural insights into the editing of germ-line-encoded interactions between T-cell receptor and MHC class II by Vα CDR3Primer sets for cloning the human repertoire of T cell Receptor Variable regions.Surface plasmon resonance for high-throughput ligand screening of membrane-bound proteinsDirected evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity.Optimizing the affinity and specificity of proteins with molecular display.How structural adaptability exists alongside HLA-A2 bias in the human αβ TCR repertoirePeriplasmic expression of soluble single chain T cell receptors is rescued by the chaperone FkpA.T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies.Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens.Innate-like control of human iNKT cell autoreactivity via the hypervariable CDR3beta loop.Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognitionStabilizing mutations increase secretion of functional soluble TCR-Ig fusion proteins.An allosteric site in the T-cell receptor Cβ domain plays a critical signalling role.Monoclonal TCR-redirected tumor cell killing.
P2860
Q24634774-D5CAC0F8-E535-48C8-B25D-FDCD46B7FA8AQ24657458-17528F33-2D41-4CF2-B11A-C2958D48F6ABQ27643687-FB7B4707-378A-4C28-B21F-65A9C8B183EAQ27643966-30949C85-A00C-41C5-BC4D-436E0A032801Q27649921-AFD0397E-21F6-4092-9E26-1F08BE7B8555Q27656470-43A235A8-C9EE-4AC7-BE88-6A201AF487E7Q27658913-8D788D0D-94BD-44BE-9184-CBF1A17AA820Q27666160-DFFB59E9-ADE0-4E07-A74B-7CB48D8F5C8CQ27666431-2516F5D2-1580-420B-A433-9311AC3D5919Q27666488-0DA934E7-7C0B-421E-820E-3EF5C7303975Q27666797-7BB18CFC-26DB-4AD9-A2F2-A2D3F361CFC1Q27672472-65E8EC16-3F83-4350-B622-7856C5738CA5Q27674375-F3DC21F7-1150-4643-B623-177775E6F882Q27675160-270D5EAD-1066-4C87-B148-662F57C498FCQ27675164-F2F78F5A-22E2-4018-A27F-CDB15734A679Q27675661-0E5776FD-3D4C-41DC-A26E-4D46D2EDD6B2Q27676136-A6DB2AFF-A3D3-4709-970D-66848E042BF2Q27676742-1A1DF0E4-B8ED-41BF-A43A-10506A06D921Q27677869-46532A26-4914-401D-853A-12A6BF4B247DQ27678265-860A91EA-6F33-4332-A8D4-76965387386CQ27678823-209E29BF-86B8-49B5-8F68-C2CDF9205899Q27680531-42701119-F27B-4C6C-B567-3CD1F52F772FQ27680546-BD89FC04-8E18-4212-A4FD-A5196B4E856DQ27682033-1ACEAEB4-1DC6-4501-A936-8CE7805C1D30Q27685375-2E953F6F-E79B-407F-955D-CDCE56463DE2Q28080312-E2BCA2F8-67A1-409A-AA6B-F695D7C142E8Q28273830-DD932D40-6CA0-44C2-9CA0-92F404AA16BDQ30847515-CD08A138-C592-4AA8-A8D6-7B2EDA114518Q30887281-4E00224E-EC69-491E-9B56-7FA0F5F6108EQ33239176-2F7268FB-8D2E-4B13-905A-76638BD5054DQ33252425-35D45DD5-5D24-4F5C-AD66-C86D382A3898Q33362590-1F8D3AFE-9C3C-4A98-AA8F-6D9132BDFBE7Q33529299-F08FAF11-D17A-4C38-BC5B-5AC2271E11DBQ33530527-C1DC8C69-88B7-443C-97F9-44E7FDBA46FBQ33613320-760091F9-CB20-4D8E-A774-1EFFF48C7EB4Q33618864-21527668-8B19-404D-8C27-4E08322E45C3Q33635226-D38D5757-6993-46D3-A395-E9AA5B2D7BC0Q33671435-C7C3F6F9-4EA0-4913-A315-462FCFD696D2Q33716306-0000D8DF-6E25-420B-9BF0-B24B783CEE93Q34273053-B9115AE3-3B5F-4F7F-9675-6D763C19C59F
P2860
Stable, soluble T-cell receptor molecules for crystallization and therapeutics.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Stable, soluble T-cell receptor molecules for crystallization and therapeutics.
@en
Stable, soluble T-cell receptor molecules for crystallization and therapeutics.
@nl
type
label
Stable, soluble T-cell receptor molecules for crystallization and therapeutics.
@en
Stable, soluble T-cell receptor molecules for crystallization and therapeutics.
@nl
prefLabel
Stable, soluble T-cell receptor molecules for crystallization and therapeutics.
@en
Stable, soluble T-cell receptor molecules for crystallization and therapeutics.
@nl
P2093
P356
P1476
Stable, soluble T-cell receptor molecules for crystallization and therapeutics.
@en
P2093
Bent K Jakobsen
Emma Baston
Jonathan M Boulter
Malkit Sami
Meir Glick
Penio T Todorov
Pierre Rizkallah
P304
P356
10.1093/PROTEIN/GZG087
P577
2003-09-01T00:00:00Z